X4 PHARMACEUTICALS, INC Interest Expense Nonoperating
X4 PHARMACEUTICALS, INC (XFOR) reported Interest Expense Nonoperating of $2.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-06
- X4 PHARMACEUTICALS, INC interest expense nonoperating for the quarter ending 2026-06-30 was $2.16M, a 3.05% decline year-over-year.
- X4 PHARMACEUTICALS, INC interest expense nonoperating for the quarter ending 2026-03-31 was $2.13M, a 3.04% decline year-over-year.
- X4 PHARMACEUTICALS, INC interest expense nonoperating for the quarter ending 2025-12-31 was $2.19M, a 5.12% decline year-over-year.
- X4 PHARMACEUTICALS, INC interest expense nonoperating for the quarter ending 2025-09-30 was $2.26M, a 6.50% decline year-over-year.
- X4 PHARMACEUTICALS, INC interest expense nonoperating for fiscal 2025 was $8.88M, a 1.23% increase from fiscal 2024.
- X4 PHARMACEUTICALS, INC interest expense nonoperating for fiscal 2024 was $8.77M, a 51.77% increase from fiscal 2023.
- X4 PHARMACEUTICALS, INC interest expense nonoperating for fiscal 2023 was $5.78M, a 44.68% increase from fiscal 2022.
- X4 PHARMACEUTICALS, INC interest expense nonoperating for fiscal 2022 was $3.99M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.16M 10-Q · filed 2026-08-06 | $4.30M 10-Q · filed 2026-08-06 | $6.48M derived: sum of 3 quarters · filed 2026-08-06 | $8.74M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.13M 10-Q · filed 2026-05-06 | $4.32M derived: sum of 2 quarters · filed 2026-05-06 | $6.58M derived: sum of 3 quarters · filed 2026-05-06 | $8.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $4.44M derived: sum of 2 quarters · filed 2026-03-17 | $6.67M derived: sum of 3 quarters · filed 2026-08-06 | $8.88M 10-K · filed 2026-03-17 |
| 2025-09-30 | $2.26M 10-Q · filed 2025-11-05 | $4.49M derived: sum of 2 quarters · filed 2026-08-06 | $6.69M 10-Q · filed 2025-11-05 | $8.99M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.23M 10-Q · filed 2026-08-06 | $4.43M 10-Q · filed 2026-08-06 | $6.74M derived: sum of 3 quarters · filed 2026-08-06 | $9.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.20M 10-Q · filed 2026-05-06 | $4.50M derived: sum of 2 quarters · filed 2026-05-06 | $6.92M derived: sum of 3 quarters · filed 2026-05-06 | $9.10M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $4.72M derived: sum of 2 quarters · filed 2026-03-17 | $6.89M derived: sum of 3 quarters · filed 2026-03-17 | $8.77M 10-K · filed 2026-03-17 |
| 2024-09-30 | $2.41M 10-Q · filed 2025-11-05 | $4.59M derived: sum of 2 quarters · filed 2025-11-05 | $6.46M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $2.18M 10-Q · filed 2025-08-08 | $4.05M 10-Q · filed 2025-08-08 | ||
| 2024-03-31 | $1.87M 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | $5.78M 10-K · filed 2026-03-17 | |||
| 2022-12-31 | $3.99M 10-K · filed 2025-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |